Logo image of RLAY

RELAY THERAPEUTICS INC (RLAY) Stock Price, Quote, News and Overview

NASDAQ:RLAY - Nasdaq - US75943R1023 - Common Stock - Currency: USD

3.25  -0.04 (-1.22%)

After market: 3.2 -0.05 (-1.54%)

RLAY Quote, Performance and Key Statistics

RELAY THERAPEUTICS INC

NASDAQ:RLAY (5/2/2025, 8:21:28 PM)

After market: 3.2 -0.05 (-1.54%)

3.25

-0.04 (-1.22%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High10.72
52 Week Low1.77
Market Cap554.09M
Shares170.49M
Float138.12M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-05 2025-05-05/amc
IPO07-16 2020-07-16


RLAY short term performance overview.The bars show the price performance of RLAY in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 -40

RLAY long term performance overview.The bars show the price performance of RLAY in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of RLAY is 3.25 USD. In the past month the price increased by 41.92%. In the past year, price decreased by -53.84%.

RELAY THERAPEUTICS INC / RLAY Daily stock chart

RLAY Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.33 351.09B
AMGN AMGEN INC 13.55 151.20B
GILD GILEAD SCIENCES INC 13.4 129.08B
VRTX VERTEX PHARMACEUTICALS INC 1728.1 128.84B
REGN REGENERON PHARMACEUTICALS 13.67 65.39B
ARGX ARGENX SE - ADR 341.93 39.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.74B
ONC BEIGENE LTD-ADR N/A 27.57B
BNTX BIONTECH SE-ADR N/A 25.23B
NTRA NATERA INC N/A 21.30B
SMMT SUMMIT THERAPEUTICS INC N/A 20.72B
BIIB BIOGEN INC 7.81 18.10B

About RLAY

Company Profile

RLAY logo image Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 261 full-time employees. The company went IPO on 2020-07-16. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. The company is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.

Company Info

RELAY THERAPEUTICS INC

399 Binney Street, 2nd Floor

Cambridge MASSACHUSETTS 02139 US

CEO: Sanjiv K. Patel

Employees: 304

RLAY Company Website

RLAY Investor Relations

Phone: 16173708837

RELAY THERAPEUTICS INC / RLAY FAQ

What is the stock price of RELAY THERAPEUTICS INC today?

The current stock price of RLAY is 3.25 USD. The price decreased by -1.22% in the last trading session.


What is the ticker symbol for RELAY THERAPEUTICS INC stock?

The exchange symbol of RELAY THERAPEUTICS INC is RLAY and it is listed on the Nasdaq exchange.


On which exchange is RLAY stock listed?

RLAY stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for RELAY THERAPEUTICS INC stock?

19 analysts have analysed RLAY and the average price target is 17.34 USD. This implies a price increase of 433.54% is expected in the next year compared to the current price of 3.25. Check the RELAY THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is RELAY THERAPEUTICS INC worth?

RELAY THERAPEUTICS INC (RLAY) has a market capitalization of 554.09M USD. This makes RLAY a Small Cap stock.


How many employees does RELAY THERAPEUTICS INC have?

RELAY THERAPEUTICS INC (RLAY) currently has 304 employees.


What are the support and resistance levels for RELAY THERAPEUTICS INC (RLAY) stock?

RELAY THERAPEUTICS INC (RLAY) has a support level at 3.09 and a resistance level at 3.26. Check the full technical report for a detailed analysis of RLAY support and resistance levels.


Is RELAY THERAPEUTICS INC (RLAY) expected to grow?

The Revenue of RELAY THERAPEUTICS INC (RLAY) is expected to decline by -70.15% in the next year. Check the estimates tab for more information on the RLAY EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy RELAY THERAPEUTICS INC (RLAY) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does RELAY THERAPEUTICS INC (RLAY) stock pay dividends?

RLAY does not pay a dividend.


When does RELAY THERAPEUTICS INC (RLAY) report earnings?

RELAY THERAPEUTICS INC (RLAY) will report earnings on 2025-05-05, after the market close.


What is the Price/Earnings (PE) ratio of RELAY THERAPEUTICS INC (RLAY)?

RELAY THERAPEUTICS INC (RLAY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.39).


What is the Short Interest ratio of RELAY THERAPEUTICS INC (RLAY) stock?

The outstanding short interest for RELAY THERAPEUTICS INC (RLAY) is 13.4% of its float. Check the ownership tab for more information on the RLAY short interest.


RLAY Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to RLAY. When comparing the yearly performance of all stocks, RLAY is a bad performer in the overall market: 90.36% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

RLAY Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to RLAY. No worries on liquidiy or solvency for RLAY as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RLAY Financial Highlights

Over the last trailing twelve months RLAY reported a non-GAAP Earnings per Share(EPS) of -2.39. The EPS increased by 14.64% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -38.76%
ROE -43.42%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%32.84%
Sales Q2Q%N/A
EPS 1Y (TTM)14.64%
Revenue 1Y (TTM)-80.42%

RLAY Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to RLAY. The Buy consensus is the average rating of analysts ratings from 19 analysts.

For the next year, analysts expect an EPS growth of 11.31% and a revenue growth -70.15% for RLAY


Ownership
Inst Owners82.86%
Ins Owners1.92%
Short Float %13.4%
Short Ratio7.28
Analysts
Analysts84.21
Price Target17.34 (433.54%)
EPS Next Y11.31%
Revenue Next Year-70.15%